| Bioactivity | Arformoterol ((R,R)-Formoterol) tartrate, the (R,R)-enantiomer of Formoterol, is a long-acting β2-adrenergic receptor (β2-AR) agonist, with a Kd of 2.9 nM. Arformoterol tartrate can be used for the research of chronic obstructive pulmonary disease (COPD)[1][2]. |
| Invitro | Arformoterol tartrate induces cAMP accumulation in cultured human bronchial epithelial cells[1]. |
| In Vivo | Arformoterol tartrate (10 ng in 0.1 ml saline/20 g body weight; intranasal instillation) mitigates Cl2-induced increases of respiratory system resistance and elastance in mice[3].Arformoterol tartrate reverses histamine- and ovalbumin-induced bronchoconstriction in guinea pigs (ED50s=1 and 40 nmol/kg, respectively)[1]. Animal Model: |
| Name | Arformoterol tartrate |
| CAS | 200815-49-2 |
| Formula | C23H30N2O10 |
| Molar Mass | 494.49 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Handley DA, et, al. Biological actions of formoterol isomers. Pulm Pharmacol Ther. 2002;15(2):135-45. [2]. Cazzola M, et, al. Arformoterol tartrate in the treatment of COPD. Expert Rev Respir Med. 2010 Apr;4(2):155-62. [3]. Song W, et, al. Postexposure administration of a {beta}2-agonist decreases chlorine-induced airway hyperreactivity in mice. Am J Respir Cell Mol Biol. 2011 Jul;45(1):88-94. |